244 results on '"Ferreira, Joao-Pedro"'
Search Results
2. Adverse events associated with early initiation of Eplerenone in patients hospitalized for acute heart failure
3. The economic contribution of U.S. seafood imports throughout the value chain: A sectorial and species-specific analysis
4. Revisiting methods for estimating interregional input-output accounts: It's not just about trade flows
5. Pathophysiological Sex Differences in Heart Failure Progression After Acute Coronary Syndrome: Insights From the EXAMINE Trial
6. conTemporary reflectiOns regarding heart failure manaGEmenT – How to ovERcome the PorTuguese barriers (TOGETHER-PT)
7. Comparison of interleukin-6 and high-sensitivity C-reactive protein for cardiovascular risk assessment: Findings from the MESA study
8. Home- versus centre-based EXercise InTervention in patients with Heart Failure (EXIT-HF trial): A pragmatic randomized controlled trial
9. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced
10. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
11. Lignocellulosic biomass pre-treatments by diluted sulfuric acid and ethanol-water mixture: A comparative techno-economic analysis
12. Changes in health-related quality of life and treatment effects in chronic heart failure: a meta-analysis
13. GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
14. Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
15. Management of Heart Failure With Reduced Ejection Fraction in Patients With Diabetes Mellitus and Chronic Kidney Disease
16. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
17. Supporting national-level policies for sustainable consumption in Portugal: A socio-economic Ecological Footprint analysis
18. Effect of eplerenone on clinical stability of Japanese patients with acute heart failure
19. Presence of Peripheral Artery Disease Is Associated With Increased Risk of Heart Failure Events: Insights From EMPEROR-Pooled
20. High- Versus Low-dose Losartan and Serum Potassium: An Analysis From HEAAL
21. Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial
22. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs
23. Inductive database to support iterative data mining: Application to biomarker analysis on patient data in the Fight-HF project
24. Making a long story short: A Multi-Importance fast-forwarding egocentric videos with the emphasis on relevant objects
25. Empagliflozin Improves Outcomes in Patients With Heart Failure and Preserved Ejection Fraction Irrespective of Age
26. Prognostic Implications of N-Terminal Pro–B-Type Natriuretic Peptide and High-Sensitivity Cardiac Troponin T in EMPEROR-Preserved
27. The Effect of Spironolactone in Patients With Obesity at Risk for Heart Failure: Proteomic Insights from the HOMAGE Trial
28. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19
29. Cardiac structure and function and quality of life associations in HFpEF: An analysis from TOPCAT-Americas
30. Impact of smoking on cardiovascular risk and premature ageing: Findings from the STANISLAS cohort
31. Cross-talk between non-alcoholic fatty liver disease and cardiovascular disease: implications for future trial design
32. Machine Learning-Derived Echocardiographic Phenotypes Predict Heart Failure Incidence in Asymptomatic Individuals
33. Towards Semantic Fast-Forward and Stabilized Egocentric Videos
34. A Reconnaissance Through the History of Shift-Share Analysis
35. Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
36. Vaccine Hesitancy Among Us Travelers
37. The Impact of Autonomous Vehicles’ Active Feedback on Trust
38. Empagliflozin Improves Cardiovascular and Renal Outcomes in Heart Failure Irrespective of Systolic Blood Pressure
39. Prognostic Importance of NT-proBNP and Effect of Empagliflozin in the EMPEROR-Reduced Trial
40. The Future of Meat: Health Impact Assessment with Randomized Evidence
41. Proteomic and Mechanistic Analysis of Spironolactone in Patients at Risk for HF
42. Interplay of Mineralocorticoid Receptor Antagonists and Empagliflozin in Heart Failure: EMPEROR-Reduced
43. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial
44. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study
45. Impact of Geographic Region on the COMMANDER-HF Trial
46. The Decline of the Experimental Paradigm During the COVID-19 Pandemic: A Template for the Future
47. Cardiovascular and Renal Outcomes of Mineralocorticoid Receptor Antagonist Use in PARAGON-HF
48. Estimating the Lifetime Benefits of Treatments for Heart Failure
49. A Systematic Literature Review in Blockchain: Benefits and Implications of the Technology for Business
50. Use of the Win Ratio in Cardiovascular Trials
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.